23 May 2012, BioSpectrum Bureau , BioSpectrum
Singapore: National Cancer Center of Japan and pharma company Daiichi Sankyo have agreed to form a comprehensive research alliance to collaborate on the creation of superior anticancer agents utilizing the research capabilities of both organizations.
This agreement is designed to integrate the high-level cancer research technology and clinical experience of the National Cancer Center with the advanced research capability and drug discovery capabilities of Daiichi Sankyo to contribute to overcoming cancer and promote public health through the development of superior anticancer agents.
Through the comprehensive collaborative relationship created as a result of this agreement, the acceleration of joint research will be made possible. The National Cancer Center will present Daiichi Sankyo with research results in line with Daiichi Sankyo's research and drug discovery policy and promote Exploratory Research for Drug Target Identification or Early Drug Discovery Research. Exploratory Research for Drug Target Identification will include exploration, identification, and evaluation of drug targets. For Early Drug Discovery Research", Daiichi Sankyo will work to acquire drug candidate compounds and antibodies through high-throughput screening.